Angiotensin II type 1 receptor A1166C gene polymorphism. Absence of an association with the risk of coronary artery disease and myocardial infarction and of a synergistic effect with angiotensin-converting enzyme gene polymorphism an the risk of these diseases

European Heart Journal

Volumn 19, Issue 11, 1998, Pages 1657-1665

  Gardemann, Andreas ^a   Nguyen, Q D ^a   Humme, J ^a   Stricker, J ^a   Katz, N ^a   Tillmanns, H ^a   Hehrlein, F W ^a   Rau, M ^b   Haberbosch, W ^b  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b KERCKHOFF HEART CENTER   (Germany)

Author keywords

Angiotensin I converting enzyme Insertion Deletion gene polymorphism; Angiotensin II type 1 receptor A1166C gene polymorphism; Cardiovascular disease; Myocardial infarction; Renin angiotensin aldosterone system; Risk factors

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CAUCASIAN; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; GENE DELETION; GENE INSERTION; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

AGED; ANGIOTENSIN II; CORONARY DISEASE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; RECEPTORS, ANGIOTENSIN; RISK FACTORS;

EID: 0032213407     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1998.1097     Document Type: Article

References (33)

1. [1] Chobanian AV, Haudenschild CC, Nickerson C et al. Anti-atherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990; 15: 327-31.
2. [2] Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cyomolgus monkeys. Cardiovasc Pharmacol 1991; 15 (Suppl 15): S65-S72.
3. [3] Powell JS, Clozel JP, Muller RKM et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989; 245: 186-8.
4. [4] Wang DH, Prewitt RL. Captopril reduces aortic and microvascular growth in hypertensive and normotensive rats. Hypertension 1990; 15: 68-77.
5. [5] The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
6. [6] Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669-77.
7. [7] Ambrosioni E, Bacchelli S, Degli Esposti D et al. ACE-inhibitors and atherosclerosis. Eur J Epidemiol 1992; 8 (Suppl 2): 129-33.
8. [8] Singer DRJ, Missouris CG, Jeffery S. Angiotensin-converting enzyme gene polymorphism. What to do about all the confusion? Circulation 1996; 94: 236-9.
9. [9] Kurtz TW. The ACE of hearts. Nature 1992; 359: 588-9.
10. [10] Cambien F, Poirier O, Lecerf L et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359: 641-4.
11. [11] Farhy RD, Ho KL, Carretero OA et al. Kinins mediate the antiproliferative effect of ramipril in rat carotid artery. Biochem Biophys Res Commun 1992; 182: 283-8.
12. [12] Pelc LR, Gross GI, Warltier DC. Mechanisms of coronary vasodilation produced by bradykinin. Circulation 1991; 83: 2048-56.
13. [13] Wiemer G, Scholkens BA, Becker RH et al. Ramiprilat enhances endothelial autocoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 1991; 18: 558-63.
14. [14] Campbell-Boswell M, Robertson AL. Effects of angiotensin II and vasopressin on human smooth muscle in vitro. Exp Mol Pathol 1981; 35: 265-7.
15. [15] Naftilan AJ, Pratt RE, Dzau VJ. Induction of platelet-derived growth factor A chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1419-24.
16. [16] Kawahara Y, Sunako M, Tsuda T et al. Angiotensin II induces expression of the c-fos gene through protein kinase C activation and calcium ion mobilization in cultured vascular smooth muscle cells. Biochem Biophys Res Commun 1988; 150: 52-9.
17. [17] Fernandez LA, Twickler J, Mead A. Neovascularization produced by angiotensin II. Lab Clin Med 1985; 105: 141-5.
18. [18] Dahlof B, Hansson L. Regression of left ventricular hypertrophy in previously untreated essential hypertension: different effects of enalapril and hydrochlorothiazid. J Hypertens 1992; 10: 1513-24.
19. [19] Regitz-Sagrosek V, Neuss M, Holzmeister J et al. Molecular biology of angiotensin receptors and their role in human cardiovascular disease. J Mol Med 1996; 74: 233-51.
20. [20] Clauser E, Curnow KM, Davies E et al. Angiotensin II receptor: proteins and gene structures expression and potential pathological involvements. Eur J Endocrinol 1996; 134: 403-11.
21. [21] Tiret L, Bonnardeaux A, Poirier O et al. Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet 1994; 344: 910-13.
22. [22] Gardemann A, Schwartz O, Weiß T et al. Gene polymorphism but not catalytic activity of angiotensin I-converting enzyme is associated to coronary artery disease and myocardial infarction in low risk patients. Circulation 1995; 92: 2796-9.
23. [23] Gensini GG. Coronary arteriography. In: Braunwald E, ed. Heart disease. Philadelphia: WB Saunders Co, 1980: 352-3.
24. [24] Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51: 606.
25. [25] Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982; 82: 2077-80.
26. [26] Kattermann R, Jaworek D, Moller G et al. Multicenter study of a new enzymatic method of cholesterol determination. Clin Chem Clin Biochem 1984; 22: 245-51.
27. [27] Fink PC, Romer M, Haeckel R et al. Measurement of proteins with the Behring nephelometer. A multicenter evaluation. J Clin Chem Clin Biochem 1989; 27: 261.
28. [28] Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol (Basel) 1957; 17: 237.
29. [29] Hingorani AD, Brown MJ. A simple molecular assay for the C1166 variant of the angiotensin II type 1 receptor gene. Biochem Biophys Res Commun 1995; 213: 725-9.
30. [30] Rigat B, Hubert C, Alhenc-Gelas F et al. An insertion/ deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-6.
31. [31] Lindpaintner K, Pfeffer MA, Kreutz R et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 1995; 332: 706-11.
32. [32] Raynolds MV, Bristow MR, Bush EW et al. Angiotensin-converting enzyme DD genotype in patients with ischemic or idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1073-5.
33. [33] Agerholm-Larsen B, Nordestgaard BG, Steffensen R et al. ACE gene polymorphism: Ischemic heart disease and longevity in 10 150 individuals. A case-referent and retrospective cohort study based on the Copenhagen City Heart Study. Circulation 1997; 95: 2358-67.